GKOS (Glaukos) Moat Score: 5/10 (As of Jun. 25, 2026)


GKOS Glaukos Corp GKOS
81 GF Score
Price $137.76
GF Value $135.40
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Glaukos Moat Score?

Glaukos GKOS +2.31% 81 Moat Score is 5 as of Jun. 25, 2026. GuruFocus rates GKOS with a GF Score™ of 81/100 and a GF Value™ of $135.40 (Fairly Valued). The stock has 6 warning signs investors should review. Among 846 Medical Devices & Instruments companies, Glaukos ranks better than 91.13% on this metric.

Glaukos has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Glaukos has Narrow Moat: Glaukos Corp has a solid narrow moat due to its valuable intellectual property and patents in ophthalmic medical devices. The company benefits from strong brand recognition and customer loyalty among ophthalmologists. However, it faces competition from larger medical device companies, limiting its ability to achieve a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Glaukos might have Narrow Moat - Solid narrow moat.

Glaukos  (NYSE:GKOS) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Glaukos Moat Score Related Terms

GKOS vs LIVN, BIO, IRTC: Moat Score Comparison

For the Medical Devices subindustry, Glaukos's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Glaukos Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Moat Score distribution charts can be found below:

* The bar in red indicates where Glaukos's Moat Score falls into.


GKOS
81GF Score
Glaukos Corp GKOS
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Glaukos (GKOS) has a Moat Score of 5 as of Jun. 25, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Glaukos ranks #75 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 8.9%.
Is Glaukos' Moat Score too high?
Glaukos' current Moat Score is 5. Based on the distribution chart, Glaukos ranks #75 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Glaukos has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Glaukos' Moat Score compare to LIVN and BIO?
According to the Medical Devices & Instruments industry distribution chart, Glaukos ranks #75 out of 846 companies for Moat Score. This places Glaukos in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Glaukos's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glaukos stock overvalued right now?
Based on GuruFocus' analysis, Glaukos (GKOS) is currently considered Fairly Valued. The stock's GF Value™ is $135.40, compared to a current price of $137.76 — trading 1.7% above its estimated fair value. The current Moat Score is 5. Glaukos' overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Glaukos (GKOS), the current Moat Score is 5 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glaukos (GKOS) Overvalued in 2026?

Based on GuruFocus' analysis, Glaukos stock appears to be overvalued. The current stock price of $137.76 is trading 1.7% above its estimated GF Value™ of $135.40. GuruFocus considers Glaukos to be Fairly Valued.

Key valuation signals for GKOS:

  • Moat Score: 5
  • GF Value™: $135.40 vs. price of $137.76 (1.7% above fair value)
  • GF Score™: 81/100 with 6 warning signs

No single metric tells the full story. See the GKOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Glaukos Business Description

Other Exchanges 6GJ:Germany
Address One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
81GF Score

Get the complete analysis for GKOS

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$137.76
Price
$135.40
GF Value